A novel quantitative ruminometric immunoassay (LIA) 
Alteration of the p53 tumour-suppressor gene or of its biological function as a cell cycle checkpoint is a frequent feature of human cancer, and may represent the rate-limiting step in the development of many tumours of all cell lineages. This alteration is usually caused by missense point mutations in the conserved regions of the gene and domains of the protein important for function or structure (Hollstein et al., 1991) . Mutant p53 protein usually undergoes conformational changes that prolong its normally very short half-life, resulting in its accumulation in the cell (Levine et al., 1991) . This has provided a convenient means of analysis using immunochemical techniques on clinical specmens, expression at detectable levels being taken as a rough measure of the presence of gene mutations. Compatible with the theory that p53 alterations predispose the cell to further genetic changes, p53 overexpression seems to be an early event in some breast tumours and to be present in non-invasive intraductal lesions (Davidoff et al., 1991) . In invasive breast cancer, p53 overexpression has been associated with aggressive tumour phenotype and shorter recurrence-free and overall survival, thus constituting a possible independent prognostic marker (Cattoretti et al., 1988; Isola et al., 1992; Thor et al., 1992; Allred et al., 1993; Barnes et al., 1993 standard (in diluent buffer: 20 mM Tris-HCI pH 7.5, 0.5 mM EDTA, 15 mM sodium chloride, 0.5% Triton-X 100, 1% BSA, 0.5 mg ml-' polyethylene glycol 6000, 0.05% sodium azide) to the antibody-coated tubes. After incubation overnight at room temperature, the tubes were washed four times with 2 ml of 0.15 M sodium chloride. The luminescence was determined using the LIA-mat starter service kit (Byk-Sangtec) and immediately measured as integrals over a period of 5 s in a 952 Berthold luminometer. The assay was standardised using pure soluble recombinant wild-type human p53 protein isolated from bacteria . The p53 protein concentration was determined with amino acid analysis. The standard curve ( Figure 1 ) was calculated with a curve-fitting programme (spline smooth Multicaic, Wallace OY, Turku Finland), the p53 content (ng ml-') being determined per RLU (relative light unit). The detection limit (zero standard + 3 standard deviations) was approximated to be (Figure 3) . Using the optimised cut-off value in univariate survival analysis, a subgroup of 62 patients (30%) whose tumours manifested p53 overexpression was identified as having a significantly shorter DFS (P = 0.003) in univariate survival analysis than patients whose tumours manifested low or no p53 expression (Table I) . The relationship to an OS did not reach statistical signifince (P = 0.10).
In multivariate survival analysis of all 205 patients, including standard prognostic factors as covariates, p53 overexpression was found to be an independent predictor of both DFS (P<0.001) and of OS (P = 0.039; Table I ).
Using the same cut-off level (0.15 ng mg-' protein), p53 overexpression was found to be related (non-significantly) to ER negativity and high S-phase fraction values ( al., 1988; Thor et al., 1992; Isola et al., 1992; Allred et al., 1993; Barnes et al., 1993; Thor and Yandell, 1993 In agreement with previous studies (Cattoretti et al., 1988; Isola et al., 1992; Thor et al., 1992; Allred et al., 1993; Banes et al., 1993) 
